Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease
Neurol 49:162-168, Lieberman,A.,et al, 1997
Efficacy of Pramipexole, A Novel Dopamine Agonist, As Monotherapy in Mild to Moderate Parkinson's Disease
Neurol 49:724-728, Shannon,K.M.,et al, 1997
Pharmacologic Profile of Ropinirole:A Nonergoline Dopamine Agonist
Neurol 49:558-562, Tulloch,I.F., 1997
Ropinirole for the Treatment of Early Parkinson's Disease
Neurol 49:393-399, Adler,C.H.,et al, 1997
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Continuous Bromocriptine Therapy in Menstrual Migraine
Neurol 48:101-102, Herzog,A.G., 1997
Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997
Double-Blind Comparison of Pramipexole & Bromocriptine Trtm with Placebo in Advanced Parkinson's Disease
Neurol 49:1060-1065, Guttman,M.,et al, 1997
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Bromocriptine and Postpartum Cerebral Angiopathy:A Causal Relationship
Neurol 46:1754-1756, Comabella,M.,et al, 1996
Diagnosis and Management of Migraine
BMJ 312:1279-1283, Goadsby,P.J.&Olesen,J., 1996
Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease
Neurol 46:1062-1065, Hutton,J.T.,et al, 1996
Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations
Neurol 47:785-788, Inzelberg,R.,et al, 1996
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995
Retroperitoneal Fibrosis in a Patient with Parkinson's Disease Treated with Pergolide
Clin NeuroPharmacol 18:277-279, Jimenez-Jimenez,F.J.,et al, 1995
Postpartum Cerebral Angiopathy Possibly Due to Bromocriptine Therapy
Stroke 26:128-130, Janssens,E.,et al, 1995
Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
The Poisoned Patient with Altered Consciousness, Controversies in the Use of a"Coma Cocktail"
JAMA 274:562-569, Hoffman,R.S.&Goldfrank,L.R., 1995
Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994
The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994
Diagnosis and Management of Pituitary Tumours
BMJ 308:1087-1091, Levy,A.&Lightman,S.L., 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Schizophrenia as a Brain Disease, The Dopamine Receptor Story
Arch Neurol 50:1093-1095, 10971993., Seeman,P., 1993
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Endogenous Benzodiazepine Receptor Ligands in Idiopathic Recurring Stupor
Lancet 340:1002-1004, Rothstein,J.D.,et al, 1992
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Treatment of Migraine
Lancet 339:1207-1209, Lance,J.W., 1992
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Acute Respiratory Failure from Dopamine Agonist Withdrawal
Neurol 42:1843-1844, Riley,D.E.,et al, 1992
An Open-Label Trial of Bromocriptine in Nonfluent Aphasia
Neurol 42:1637-1638, Sabe,L.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992